Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli.

Autor: Monteiro-Neto V; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.; Universidade Federal do Maranhão, São Luís, MA, Brazil., de Souza CD; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Gonzaga LF; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., da Silveira BC; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.; Faculdades Pequeno Príncipe, Curitiba, PR, Brazil., Sousa NCF; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Pontes JP; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Santos DM; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Martins WC; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Pessoa JFV; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Carvalho Júnior AR; Department of Parasitology, Universidade de São Paulo, São Paulo, SP, Brazil., Almeida VSS; Universidade Federal do Maranhão, São Luís, MA, Brazil., de Oliveira NMT; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.; Faculdades Pequeno Príncipe, Curitiba, PR, Brazil., de Araújo TS; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Maria-Ferreira D; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.; Faculdades Pequeno Príncipe, Curitiba, PR, Brazil., Mendes SJF; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Ferro TAF; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil., Fernandes ES; Programa de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.; Universidade Federal do Maranhão, São Luís, MA, Brazil.; Faculdades Pequeno Príncipe, Curitiba, PR, Brazil.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2020 May 14; Vol. 15 (5), pp. e0232987. Date of Electronic Publication: 2020 May 14 (Print Publication: 2020).
DOI: 10.1371/journal.pone.0232987
Abstrakt: Escherichia coli and Staphylococcus aureus are important agents of urinary tract infections that can often evolve to severe infections. The rise of antibiotic-resistant strains has driven the search for novel therapies to replace the use or act as adjuvants of antibiotics. In this context, plant-derived compounds have been widely investigated. Cuminaldehyde is suggested as the major antimicrobial compound of the cumin seed essential oil. However, this effect is not fully understood. Herein, we investigated the in silico and in vitro activities of cuminaldehyde, as well as its ability to potentiate ciprofloxacin effects against S. aureus and E. coli. In silico analyses were performed by using different computational tools. The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde. For analysis of the possible toxic effects and the theoretical pharmacokinetic parameters of the compound, the Osiris, SwissADME and PROTOX programmes were used. Estimations of cuminaldehyde gastrointestinal absorption, blood brain barrier permeability and skin permeation by using SwissADME; and drug likeness and score by using Osiris, were also evaluated The in vitro antimicrobial effects of cuminaldehyde were determined by using microdilution, biofilm formation and time-kill assays. In silico analysis indicated that cuminaldehyde may act as an antimicrobial and as a membrane permeability enhancer. It was suggested to be highly absorbable by the gastrointestinal tract and likely to cross the blood brain barrier. Also, irritative and harmful effects were predicted for cuminaldehyde if swallowed at its LD50. Good oral bioavailability and drug score were also found for this compound. Cuminaldehyde presented antimicrobial and anti-biofilm effects against S. aureus and E. coli.. When co-incubated with ciprofloxacin, it enhanced the antibiotic antimicrobial and anti-biofilm actions. We suggest that cuminaldehyde may be useful as an adjuvant therapy to ciprofloxacin in S. aureus and E. coli-induced infections.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje